Comparison of hyperbaric oxygen versus iloprost treatment in an experimental rat central retinal artery occlusion model

Karaman, Suleyman Korhan; Özkan, Berna; Yazır, Yusufhan; Yardımoğlu, Melda; Gök, Mustafa; Kara, Özgür; Vural, Çiğdem; Rençber, Selenay Furat; Emek, Salih Kaan

doi:10.1007/s00417-016-3444-5

Cited by 4 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBOT also decrease edema and preserve compromised tissue adjacent to ischaemic area [1,2,8]. Karaman et al demonstrated, in mice models of CRAO, that the apoptotic index of retinal inner cells was lower in the group submitted to HBOT in the reperfusion phase than in control group [12]. Also in an animal experiment in a CRAO mice model, Gaydar et al showed that HBOT diminished cell loss from 58% to 30%, which was related to increased survival of cells in the retinal inner layer [13].…”

Section: Introductionmentioning

confidence: 99%

Hyperbaric Oxygen Therapy in Retinal Arterial Occlusion: Epidemiology, Clinical Approach, and Visual Outcomes

Lopes

Basto

Henriques

et al. 2019

Case Reports in Ophthalmological Medicine

View full text Add to dashboard Cite

properly cited.Purpose. To evaluate the e cacy and safety of hyperbaric oxygen therapy (HBOT) in patients with acute retinal artery occlusion (RAO). Secondarily, to analyse the epidemiology and the clinical approach. Methods. Retrospective study of 13 patients submitted to HBOT between 2013 and 2018. e analysed parameters consisted of: systemic history, time between symptoms onset and treatment, initial approach, number of HBOT sessions, complications of HBOT and best corrected visual acuity-BCVA (of the total sample, central RAO-CRAO-group, and branch RAO-BRAO group). Results. Arterial hypertension was the most prevalent systemic risk factor (53.8%). Initial therapies were 100% normobaric oxygen administration, topical and oral hypotensive medication, eye massage and aspirin. CRAO was observed in 69.2% and BRAO in 30.8% of the cases, with clinically signi cant visual improvement (a decrease in logMAR of 0.3) in 55.5% and 75%, respectively. Time between symptoms onset and treatment had a median of 9 hours. e median number of HBOT sessions was 7, without complications. Conclusions. HBOT provide BCVA improvement in patients with RAO, when it is performed in an early time a er the symptom onset. It seems to be an e ective and safe therapeutic option for a pathology that still remains without approved treatment.

show abstract

Section: Introductionmentioning

confidence: 99%